Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)
Clinical trial NCT03944252 · UNKNOWN
Trial details
- NCT number
- NCT03944252
- Sponsor
- Gruppo Oncologico del Nord-Ovest
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-18
- Primary completion
- 2021-02-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.